DK1381356T3 - Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose - Google Patents
Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel scleroseInfo
- Publication number
- DK1381356T3 DK1381356T3 DK02763962T DK02763962T DK1381356T3 DK 1381356 T3 DK1381356 T3 DK 1381356T3 DK 02763962 T DK02763962 T DK 02763962T DK 02763962 T DK02763962 T DK 02763962T DK 1381356 T3 DK1381356 T3 DK 1381356T3
- Authority
- DK
- Denmark
- Prior art keywords
- trifluoromethylphenyl
- cyano
- amide
- hydroxy
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28168501P | 2001-04-05 | 2001-04-05 | |
GBGB0123571.2A GB0123571D0 (en) | 2001-04-05 | 2001-10-02 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
PCT/US2002/010773 WO2002080897A1 (en) | 2001-04-05 | 2002-04-04 | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1381356T3 true DK1381356T3 (da) | 2008-09-22 |
Family
ID=26246599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02763962T DK1381356T3 (da) | 2001-04-05 | 2002-04-04 | Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1381356B1 (da) |
AR (1) | AR033459A1 (da) |
AT (1) | ATE396719T1 (da) |
CA (1) | CA2443285C (da) |
CY (1) | CY2014004I2 (da) |
DE (1) | DE60226855D1 (da) |
DK (1) | DK1381356T3 (da) |
ES (1) | ES2305287T3 (da) |
FR (1) | FR14C0010I2 (da) |
LU (1) | LU92366I2 (da) |
PA (1) | PA8542901A1 (da) |
PT (1) | PT1381356E (da) |
SI (1) | SI1381356T1 (da) |
UY (1) | UY27244A1 (da) |
WO (1) | WO2002080897A1 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003293500A1 (en) | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
SG142305A1 (en) * | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
JP5021488B2 (ja) | 2004-12-21 | 2012-09-05 | メルク セローノ ソシエテ アノニム | スルホニルアミノ環式誘導体及びその使用 |
DK1844032T3 (da) | 2005-01-31 | 2011-10-24 | Merck Serono Sa | N-hydroxyamid-derivater og deres anvendelse |
CA2616479A1 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
EP2100881A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Pyrimidyl- or pyridinylaminobenzoic acid derivatives |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
EP2277515A1 (en) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
MX336663B (es) | 2009-09-18 | 2016-01-27 | Sanofi Sa | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada. |
EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
US20140031383A1 (en) | 2011-02-08 | 2014-01-30 | Dana-Farber Cancer Institute, Inc. | Methods for treatment of melanoma |
EP2762135A1 (en) * | 2013-02-04 | 2014-08-06 | Sanofi | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
GR1010137B (el) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES448386A1 (es) | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
TW314467B (da) | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
-
2002
- 2002-04-04 AT AT02763962T patent/ATE396719T1/de active
- 2002-04-04 EP EP02763962A patent/EP1381356B1/en not_active Expired - Lifetime
- 2002-04-04 ES ES02763962T patent/ES2305287T3/es not_active Expired - Lifetime
- 2002-04-04 PT PT02763962T patent/PT1381356E/pt unknown
- 2002-04-04 SI SI200230727T patent/SI1381356T1/sl unknown
- 2002-04-04 DE DE60226855T patent/DE60226855D1/de not_active Expired - Lifetime
- 2002-04-04 EP EP08004647A patent/EP1935416A3/en not_active Ceased
- 2002-04-04 DK DK02763962T patent/DK1381356T3/da active
- 2002-04-04 WO PCT/US2002/010773 patent/WO2002080897A1/en not_active Application Discontinuation
- 2002-04-04 AR ARP020101245A patent/AR033459A1/es not_active Application Discontinuation
- 2002-04-04 CA CA002443285A patent/CA2443285C/en not_active Expired - Fee Related
- 2002-04-05 PA PA20028542901A patent/PA8542901A1/es unknown
- 2002-04-05 UY UY27244A patent/UY27244A1/es unknown
-
2014
- 2014-01-23 CY CY2014004C patent/CY2014004I2/el unknown
- 2014-01-29 LU LU92366C patent/LU92366I2/fr unknown
- 2014-02-05 FR FR14C0010C patent/FR14C0010I2/fr active Active
Also Published As
Publication number | Publication date |
---|---|
ATE396719T1 (de) | 2008-06-15 |
WO2002080897A1 (en) | 2002-10-17 |
DE60226855D1 (de) | 2008-07-10 |
LU92366I2 (fr) | 2014-03-31 |
PT1381356E (pt) | 2008-07-24 |
FR14C0010I2 (fr) | 2014-11-21 |
EP1381356A1 (en) | 2004-01-21 |
AR033459A1 (es) | 2003-12-17 |
UY27244A1 (es) | 2002-07-31 |
SI1381356T1 (sl) | 2008-12-31 |
EP1935416A2 (en) | 2008-06-25 |
FR14C0010I1 (da) | 2014-03-14 |
PA8542901A1 (es) | 2003-11-12 |
CA2443285C (en) | 2007-08-21 |
CY2014004I1 (el) | 2015-12-09 |
EP1381356B1 (en) | 2008-05-28 |
EP1935416A3 (en) | 2008-10-22 |
ES2305287T3 (es) | 2008-11-01 |
CA2443285A1 (en) | 2002-10-17 |
CY2014004I2 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1381356T3 (da) | Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose | |
DK1425001T3 (da) | Phenethanolaminderivater til behandling af respiratoriske sygdomme | |
NO20042680L (no) | Fremgangsmater for fremstilling av O-demetylvenflaxine | |
DK1458447T3 (da) | Kombination af cytokrom-p450-beroende proteasinhibitorer | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
IS6954A (is) | Notkun á enantíómerískt hreinu essítalóprami | |
DK1411926T3 (da) | Integrininhibitorer til behandling af öjensygdomme | |
DE60121951D1 (de) | Charakterisierung nichtlinearen Verhaltens | |
DE60217089D1 (de) | Lipidsenkende biphenylcarbonsäureamide | |
DK1377544T3 (da) | Oprensning af 2-nitro-4-methylsulfonylbenzoesyre | |
NO20041968L (no) | Anvendelse av cystationin | |
DK1556026T3 (da) | Hidtil ukendt farmaceutiske formuleringer af modafinil | |
NO20042502L (no) | Farmasoytisk formulering omfattende bicalutamid | |
DE60220914D1 (de) | Aminoacetonitril-verbindungen zur bekämpfung von endoparasiten | |
NO20042613L (no) | Ny anvendelse for behandling av gastroosofagial refluks | |
DK1427724T3 (da) | Hidtil ukendt anvendelse af substituerede aminomethylchromaner | |
DE50205590D1 (de) | Ummantelung von leiterbahnen | |
DE60201909D1 (de) | Zoom-verfahren | |
DK1373245T3 (da) | Mellemprodukter til fremstilling af spinosyner | |
DK1187612T3 (da) | Anvendelse af riluzol til behandling af multipel sclerose | |
ITMI20021039A0 (it) | Depurazione di elettrodi di un elettrofiltro | |
SM200100023B (it) | Dispositivo di aggancio temporaneo, particolarmente per componenti di strutture modulari rimovibili | |
SE0100623D0 (sv) | Safty four | |
UA7542S (uk) | Комплект етикеток | |
UA5031S (uk) | Комплект етикеток |